These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28413214)

  • 1. Circulating Biomarkers for Predicting Infliximab Response in Rheumatoid Arthritis: A Systematic Bioinformatics Analysis.
    Huang QL; Zhou FJ; Wu CB; Xu C; Qian WY; Fan DP; Cai XS
    Med Sci Monit; 2017 Apr; 23():1849-1855. PubMed ID: 28413214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis.
    Thomson TM; Lescarbeau RM; Drubin DA; Laifenfeld D; de Graaf D; Fryburg DA; Littman B; Deehan R; Van Hooser A
    BMC Med Genomics; 2015 Jun; 8():26. PubMed ID: 26036272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study.
    Nakamura S; Suzuki K; Iijima H; Hata Y; Lim CR; Ishizawa Y; Kameda H; Amano K; Matsubara K; Matoba R; Takeuchi T
    Arthritis Res Ther; 2016 Jul; 18():159. PubMed ID: 27435242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Derlin-1, as a Potential Early Predictive Biomarker for Nonresponse to Infliximab Treatment in Rheumatoid Arthritis, Is Related to Autophagy.
    Cai Y; Xu K; Aihaiti Y; Li Z; Yuan Q; Xu J; Zheng H; Yang M; Wang B; Yang Y; Yang Y; Xu P
    Front Immunol; 2021; 12():795912. PubMed ID: 35046954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profile predicting the response to anti-TNF treatment in patients with rheumatoid arthritis; analysis of GEO datasets.
    Kim TH; Choi SJ; Lee YH; Song GG; Ji JD
    Joint Bone Spine; 2014 Jul; 81(4):325-30. PubMed ID: 24561023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis.
    Lequerré T; Gauthier-Jauneau AC; Bansard C; Derambure C; Hiron M; Vittecoq O; Daveau M; Mejjad O; Daragon A; Tron F; Le Loët X; Salier JP
    Arthritis Res Ther; 2006; 8(4):R105. PubMed ID: 16817978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential of circulating microRNA-125a and microRNA-125b as markers for inflammation and clinical response to infliximab in rheumatoid arthritis patients.
    Cheng P; Wang J
    J Clin Lab Anal; 2020 Aug; 34(8):e23329. PubMed ID: 32281166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study.
    Talotta R; Berzi A; Atzeni F; Dell'Acqua D; Sarzi Puttini P; Trabattoni D
    Reumatismo; 2016 Sep; 68(2):83-9. PubMed ID: 27608796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.
    Julià A; Barceló M; Erra A; Palacio C; Marsal S
    Pharmacogenomics; 2009 Oct; 10(10):1697-708. PubMed ID: 19842941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-treatment whole blood gene expression is associated with 14-week response assessed by dynamic contrast enhanced magnetic resonance imaging in infliximab-treated rheumatoid arthritis patients.
    MacIsaac KD; Baumgartner R; Kang J; Loboda A; Peterfy C; DiCarlo J; Riek J; Beals C
    PLoS One; 2014; 9(12):e113937. PubMed ID: 25504080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
    Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
    Lindberg J; af Klint E; Catrina AI; Nilsson P; Klareskog L; Ulfgren AK; Lundeberg J
    Arthritis Res Ther; 2006; 8(6):R179. PubMed ID: 17134501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study.
    Lourido L; Ruiz-Romero C; Picchi F; Diz-Rosales N; Vilaboa-Galán S; Fernández-López C; Tasende JAP; Pérez-Pampín E; Regueiro C; Mera-Varela A; Gonzalez A; Hambardzumyan K; Saevarsdottir S; Nilsson P; Blanco FJ
    Semin Arthritis Rheum; 2020 Oct; 50(5):1101-1108. PubMed ID: 32920323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
    Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
    Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
    Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
    Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis.
    Trocmé C; Marotte H; Baillet A; Pallot-Prades B; Garin J; Grange L; Miossec P; Tebib J; Berger F; Nissen MJ; Juvin R; Morel F; Gaudin P
    Ann Rheum Dis; 2009 Aug; 68(8):1328-33. PubMed ID: 18664547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.